Background-In animal models of circulatory shock and heart failure concentrations of the endogenous opioid peptide # endorphin are raised and opioid recep To allow some clarification of the relation between the duration and severity of myocardial ischaemia and the release of, endorphin we studied two groups of patients. Study 1 Fifty five consecutive patients admitted to the coronary care unit of Glasgow Royal Infirmary with a clinical diagnosis of acute myocardial ischaemia were studied. Myocardial infarction was confirmed by the presence of at least two of the three standard criteria: a compatible history ofchest pain, typical evolving electrocardiographic changes, and an increase in the concentration of creatine kinase to above twice the upper limit of normal. Patients without these features but with evidence of ischaemia were considered to have unstable angina. Daily clinical examinations were performed and when there was evidence of pulmonary congestion radiological confirmation was sought. Cross sectional echocardiography was performed on day three, and where image quality allowed, we calculated the ejection fraction using apical two and four chamber views and a modified Simpson's formula.'5 Serial blood samples were taken from the time of admission to six weeks after discharge. Patients were asked to quantify the intensity of their chest pain on a 100 mm noncalibrated linear visual analogue scale cued with "very mild" and "very severe". 
release of # endorphin in humans.
Methods-Observational study in a university cardiology centre. Serial measurements of endorphin made by specific radioimmunoassay were correlated with other clinical and neuroendocrine variables that were measured prospectively. Fifty five patients with acute myocardial ischaemia and 26 patients undergoing elective coronary angioplasty of the left anterior descending coronary artery were studied.
Result&-# endorphin concentrations were raised above the upper limit of normal in 31/42 (74%) patients with confirmed myocardial infarction, 3/13 (23%) patients with unstable angina, and 10/24 (42%) patients after coronary angioplasty. There was no evidence of myocardial release of endorphin. There were significant positive correlations between # endorphin and the concentrations of adrenocorticotrophic hormone, cortisol, and arginine vasopressin. In patients with acute myocardial ischaemia there was a significant positive correlation between the peak concentrations ofcreatine kinase and # endorphin but no correlation with visual analogue scores of the intensity of chest pain. The highest # endorphin concentrations were seen in patients whose clinical course was complicated by the development of heart failure.
Conclusions---endorphin release is a component of the neuroendocrine activation associated with myocardial ischaemia/infarction. 
Patients

METHODS
To allow some clarification of the relation between the duration and severity of myocardial ischaemia and the release of, endorphin we studied two groups of patients. Study 1 Fifty five consecutive patients admitted to the coronary care unit of Glasgow Royal Infirmary with a clinical diagnosis of acute myocardial ischaemia were studied. Myocardial infarction was confirmed by the presence of at least two of the three standard criteria: a compatible history ofchest pain, typical evolving electrocardiographic changes, and an increase in the concentration of creatine kinase to above twice the upper limit of normal. Patients without these features but with evidence of ischaemia were considered to have unstable angina. Daily clinical examinations were performed and when there was evidence of pulmonary congestion radiological confirmation was sought. Cross sectional echocardiography was performed on day three, and where image quality allowed, we calculated the ejection fraction using apical two and four chamber views and a modified Simpson's formula. ' Fifty five consecutive patients (37 male, aged admitted to the coronary care unit with acutc myocardial ischaemia were studied.
Raised plasma concentrations of # endorphin were detected in 31/42 (74%) patients with confirmed myocardial infarction (peak 12-0 (6-9-26 0) pmol/l) and in 3/13 (23%) patients with unstable angina (peak 4.5 (2 7-7 0) pmol/ 1) (fig 1) . The highest concentration recorded was 98-8 pmol/l and occurred in a patient who subsequently developed cardiogenic shock and died. Figure 2 shows the time course of the change in /3 endorphin concentration for all 55 patients. There were no significant differences in /3 endorphin concentrations at any time point between patients who had and had not received thrombolytic therapy. The 12 patients with myocardial infarction who developed cardiac failure in hospital had a higher peak # endorphin concentration that those with an uncomplicated course (29-2 (9 9-51 5) v 9-6 (3-8-22 4) pmol/l (fig 1) . Hours two related hormones. In 12 (22%) peak ACTH was higher than normal and was 2-18 fold higher than the peak ft endorphin concentration. In five the opposite pattern was seen, with peak f endorphin being 2-8 fold higher than peak ACTH. Figure 3 shows individual examples of these patterns. The peak concentration of arginine vasopressin in patients with myocardial infarction was significantly higher than in patients with unstable angina (9 0 (3-3-17-8) v 1-0 (0-8-2 9) pg/ml (p = 0 0002)) and considering all patients peak arginine vasopressin correlated well with peak ft endorphin (r = 0-59, p = 0-001).
Peak concentrations of ft endorphin and creatine kinase were positively correlated ( fig 4) and there was a negative correlation between the time from onset of symptoms to peak ft endorphin concentrations (r = -0-38, p = 0-005). Though pain is a stimulus to # endorphin release, there was no significant correlation with pain scores. These were virtually identical in the patients with and without myocardial infarction (78 (65-86) v 76 (63-86) and those with and without cardiac failure (79 (57-84) v 78 (67-86)).
No significant correlations were seen with age, Norris score, ejection fraction on day three, and systolic or diastolic blood presure or heart rate on admission. STUDY 
2
All 26 patients had a technically successful angioplasty. In three patients concentrations of ft endorphin in the great cardiac vein were > 1 0 pmol/l (2SD of the measurement error) higher than those in the aorta. But overall concentrations in the aorta and great cardiac vein were similar at both time points. There was thus no consistent evidence of any myocardial release and accordingly only the concentrations in the great cardiac vein are reported. At To only two patients had # endorphin concentrations > 7-2 pmol/l (upper limit of normal): one of these had an episode of severe angina during transfer to the catheter laboratory and the other had a difficult arterial cannulation. Both of these patients were excluded from further analysis. correlation between endorphin concentrations and creatine kinase, a marker of ischaemic damage. There was a negative correlation between the duration of ischaemia (assessed from patient symptoms) and endorphin concentrations. This latter finding suggests that endorphin is released as a single pulse at the onset of myocardial ischaemia with the highest concentrations being found the earlier the patient is seen. In the angioplasty patients, in whom the period of coronary artery occlusion was much shorter, there was again only a weak correlation between ft endorphin and a biochemical marker of ischaemia and no correlation at all with the electrical evidence of ischaemia. The persistence of a negative correlation with the duration of ischaemia (balloon inflation time) in this second patient group is consistent with the release of a single pulse of f endorphin-in this case within minutes of the ischaemic stress being applied. In the patients with unstable angina, myocardial ischaemia was present but there was virtually no ft endorphin release. Thus overall there is no convincing evidence that the fi endorphin release is primarily determined by either the duration or the objective severity of the ischaemic insult.
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